“In surgery, we anticipate FDA approval for the OTTAVA robotic surgical system and the EMEA launch of ETHICON 4000.”

In context

“nal first-in-class, once-daily oral therapy for metastatic castration-resistant prostate cancer. This will be the first clinical readout from an ongoing study from our recent Ambrx acquisition. We are also expecting data readouts for INLEXZO in high-risk non-muscle invasive bladder cancer, ICOTYDE in psoriatic arthritis, and CAPLYTA in bipolar mania. Turning to MedTech, there are several important catalysts that we expect to generate momentum. In cardiovascular, we expect launches for the Dual Energy THERMOCOOL SMARTTOUCH SF platform, as well as the Shockwave C2 Aero and AeroFly IVL catheters. In electrophysiology, we expect continued adoption of CARTOSOUND SONATA cardio mapping in the U.S. and VARIPULSE Pro in EMEA, with anticipated approval of VARIPULSE Pro in the U.S. later this year. In surgery, we anticipate FDA approval for the OTTAVA robotic surgical system and the EMEA launch of ETHICON 4000. In vision, we continue to expand availability of the TECNIS PureSee intraocular lens for cataracts and presbyopia while driving adoption of ACUVUE OASYS MAX lenses. Finally, the orthopedics business had another quarter of improvement. We continue to evaluate all separation options that create shareholder value and set the DePuy Synthes business up for success long term. We are pleased with the progress made, are on track for a mid-2027 separation, and look forward to sharing updates later this year. To wrap up before we take your questions, our first half performance illustrates the strength and resilience of our portfolio, the momentum we are building behind our new products, and the steady progress we are making across our pipeline. Strategic focus, scale, and financial flexibility to”